Wire · operational-macro
Bright Minds Biosciences' Application for Seizure Drug Gets Put on Hold by FDA
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 2 November 2026 · Fusion42 review
Bright Minds Biosciences' FDA application for their seizure drug BMB-101 was put on partial clinical hold due to toxicity concerns in mice and insufficient pharmacokinetic and juvenile toxicity data to support pediatric trials. The company plans to clarify with the FDA and adjust its study accordingly, but ongoing trials are unaffected.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.
◆ ◆ The Wire takeaway
You must revise your seizure drug trial if your startup targets pediatric use in the US, as FDA safety concerns on animal toxicity raise new hurdles. The pediatric epilepsy drug market is temporarily tougher to enter until regulator feedback clears.
◆ Coverage
2 sources · 2 Nov 2026
◆ Related on Wire
◆ Topics